Eribulin mesylate exerts antitumor effects via CD103
Eribulin mesylate (ERB) is a synthetic analog of halichondrin B, inhibiting tumor cell growth by disrupting microtubule function. Recently, anticancer drugs have been shown to not only act directly on tumor cells but also to exert antitumor effects by modifying the tumor environment. Although ERB ha...
Saved in:
| Main Authors: | Kazumasa Oya, Yoshiyuki Nakamura, Rei Watanabe, Ryota Tanaka, Yuki Ichimura, Noriko Kubota, Yutaka Matsumura, Hideaki Tahara, Naoko Okiyama, Manabu Fujimoto, Toshifumi Nomura, Yasuhiro Fujisawa |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2218782 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-effectiveness analysis of eribulin versus dacarbazine in patients with advanced liposarcoma
by: Miaomiao Zhang, et al.
Published: (2025-01-01) -
Real world analysis of the efficacy and safety of eribulin compared to utidelone in combination with capecitabine for the treatment of metastatic breast cancer
by: Mengya Feng, et al.
Published: (2024-12-01) -
Vitiligo-like lesions following imatinib mesylate therapy: a case series and review of literature
by: Neerja Saraswat, et al.
Published: (2024-01-01) -
OCCURRENCE OF SECONDARY MALIGNANCIES IN CHRONIC MYELOID LEUKEMIA DURING THERAPY WITH IMATINIB MESYLATE-SINGLE INSTITUTION EXPERIENCE
by: Grzegorz Helbig, et al.
Published: (2015-01-01) -
THE EFFECT OF IMATINIB MESYLATE IN NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE, CHRONIC-PHASE MYELOID LEUKEMIA IN SUB-SAHARAN AFRICAN PATIENTS: THE EXPERIENCE OF CÔTE D’IVOIRE
by: GUSTAVE Kouassi KOFFI, et al.
Published: (2014-08-01)